
Biopharmaceutical Manufacturer

Pharmaceutical Technology Research and Development Provider

Pharmaceutical R&D Manufacturer
On May 12, Pfizer and AstraZeneca announced nearly US$1 billion in new investments in France combined, ahead of this year's annual "Choose France" business summit.
Pfizer announced an investment of 500 million euros ($538.5 million) to strengthen its R&D efforts in France, while AstraZeneca declared a $388 million investment for its facility in Dunkirk.
In recent years, countries have been striving to attract foreign investment.
France's annual "Choose France" event aims to attract large overseas companies and investors.
In addition to Pfizer, AstraZeneca, and GSK,Wall Street bank Morgan Stanley announced that it will add 100 jobs in Paris and launch new projects, while other companies such as German airline Lilium will also invest in France.In the home furnishings sector, IKEA Group will invest 906 million euros between 2023 and 2026, while German building materials manufacturer Knauf will also invest 100 million euros. In the technology sector, Nokia will add 500 R&D jobs over the next 5 to 8 years. In the agrifood sector, U.S.-based Mars, Incorporated announced an investment of 130 million euros.
France hopes to enhance Paris's position as Europe's top business capital.
But Paris has consistently lagged behind New York and London on a global scale.The highly anticipated Z/Yen Global Financial Centres Index, released in March this year, ranked New York as the top global financial center, with London in second place. The survey placed Paris at 14th.

▲Z/Yen March 2023 Global Financial Centres Graphic


Pharmaceuticals | Biological Drugs | ADC | mRNA | CAR—T | PD-1 | Medical Device | Imaging | IVD | Cardiovascular | Orthopedics | Oral | Ophthalmology | Surgical Robot | Internet Healthcare| Hospital | CXO | Life ScienceStudy
Deep Original | Annual Review | Trend Analysis | Cross-Cycle Series | Stock Market Dynamics | Enterprise Dynamics | Executive Moves | Pharmaceutical Financial Reports | Medical Device Financial Report | Major M&A | Strategic Split | Exclusive Interview with Senior Executives | Compensation | Policy Analysis | Medical Insurance Negotiation | DRG/DIP | Centralized Procurement | JPM | Latest News | CIIE | CMEF
Medical Device Rankings | Medtronic | Abbott | Johnson & Johnson Medical | Siemens Healthineers | BD | Stryker | GE Healthcare | Roche Diagnostics | Philips | Boston Scientific | Mindray Medical | United Imaging Healthcare | Minimally Invasive Medical | Lepu Medical | Weigao | Danaher | Thermo Fisher
Pharmaceutical Rankings | Pfizer | AbbVie | Roche Pharmaceuticals | Johnson & Johnson Pharmaceutical | Merck & Co. | AstraZeneca | Bristol-Myers Squibb | Sanofi | Novartis | GSK | Hengrui | BeiGene | CSPC | Innovent Biologics | Junshi Biosciences | Legend Biotech | I-Mab Biopharma | CStone Pharmaceuticals | Rongchang Bio | Zai Lab | WuXi AppTec | Qiming Venture Partners | Lilly Asia
